JP2002501499A - 免疫調節剤の用途 - Google Patents
免疫調節剤の用途Info
- Publication number
- JP2002501499A JP2002501499A JP54685698A JP54685698A JP2002501499A JP 2002501499 A JP2002501499 A JP 2002501499A JP 54685698 A JP54685698 A JP 54685698A JP 54685698 A JP54685698 A JP 54685698A JP 2002501499 A JP2002501499 A JP 2002501499A
- Authority
- JP
- Japan
- Prior art keywords
- camp
- cells
- use according
- camps
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
- C12N2310/121—Hammerhead
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 免疫抑制疾患処置用の製薬剤調製物の製造への、cAMP依存性プロテインキ ナーゼAタイプIの機能を廃止する阻害剤の使用。 2. 前記阻害剤が、cAMP拮抗剤、ハンマーヘッドのリボザイム、配列特異的ア ンチセンスヌクレオチドおよびアンカー作用破壊ペプチドからなる群から選択さ れる請求項1に記載の使用。 3. 前記cAMP拮抗剤が、Rp-8-Br-cAMPS、Rp-8-Br-モノブチリル-cAMPS、Rp-モ ノ-ブチリル-CAMPS、Rp-8-Cl-cAMPS、Rp-8-(4-クロロフェニルチオール)-cAMPS およびRp-8-ピペリジノ-cAMPSからなる群から選択される請求項1または2に記 載の使用。 4. 前記cAMP拮抗剤が、Rp-8-Br-cAMPSである請求項1〜3の何れかに記載の 使用。 5. 前記ハンマーヘッドのリボザイムが、下記の基本配列: を有する請求項1または2に記載の使用。 6. 前記ハンマーヘッドのリボザイムが、下記の基本配列: を有する請求項1または2に記載の使用。 7. 前記ハンマーヘッドのリボザイムが、2-デオキシ-シトシンおよび2-デオ キシ-ウラシル類似体の導入により安定化されている請求項6に記載の使用。 8. 前記配列特異的アンチセンスヌクレオチドが、下記の配列: を有する請求項1または2に記載の使用。 9. 前記配列特異的アンチセンスヌクレオチドが、下記の配列:を有する請求項1または2に記載の使用。 10. 前記競争アンカー作用破壊ペプチドが、少なくとも22個のアミノ酸を 含有する請求項1または2に記載の使用。 11. 前記アミノ酸が、 である請求項10に記載の使用。 12. 前記アミノ酸が、 である請求項10に記載の使用。 13. 前記アミノ酸が、 である請求項10に記載の使用。 14. 前記アミノ酸が、である請求項10に記載の使用。 15. 前記免疫抑制疾患が、ヒト免疫不全ウイルス感染または共通の不定免疫 不全である請求項1〜14の何れかに記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO971997A NO971997D0 (no) | 1997-04-29 | 1997-04-29 | Bruk av immunmodulerende midler |
NO971997 | 1997-04-29 | ||
PCT/NO1998/000134 WO1998048809A1 (en) | 1997-04-29 | 1998-04-29 | Use of immunomodulating agents |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009295046A Division JP2010111688A (ja) | 1997-04-29 | 2009-12-25 | 免疫調節剤の用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002501499A true JP2002501499A (ja) | 2002-01-15 |
JP2002501499A5 JP2002501499A5 (ja) | 2005-12-02 |
Family
ID=19900676
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54685698A Pending JP2002501499A (ja) | 1997-04-29 | 1998-04-29 | 免疫調節剤の用途 |
JP2009295046A Pending JP2010111688A (ja) | 1997-04-29 | 2009-12-25 | 免疫調節剤の用途 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009295046A Pending JP2010111688A (ja) | 1997-04-29 | 2009-12-25 | 免疫調節剤の用途 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20050250727A1 (ja) |
EP (1) | EP1024809B1 (ja) |
JP (2) | JP2002501499A (ja) |
AT (1) | ATE213944T1 (ja) |
AU (1) | AU738674B2 (ja) |
CA (1) | CA2288215C (ja) |
DE (1) | DE69804125T2 (ja) |
DK (1) | DK1024809T3 (ja) |
ES (1) | ES2171018T3 (ja) |
NO (1) | NO971997D0 (ja) |
NZ (1) | NZ501181A (ja) |
PT (1) | PT1024809E (ja) |
WO (1) | WO1998048809A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010503652A (ja) * | 2006-09-15 | 2010-02-04 | ローラス エーエス | (Rp)−8−置換cAMPSを製造する方法 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999062315A2 (en) * | 1998-05-27 | 1999-12-02 | Lauras As | Method for altering the activity of proteins of the pka signaling pathway |
MXPA01007366A (es) * | 1999-01-21 | 2002-06-04 | Metamorphix Inc | Inhibidores de factores de crecimiento y diferenciacion y usos de los mismos. |
WO2001042470A1 (en) * | 1999-12-07 | 2001-06-14 | University Of Medicine And Dentistry Of New Jersey | Nucleic acid and protein expressed thereby and their involvement in stress |
US6958214B2 (en) * | 2000-07-10 | 2005-10-25 | Sequenom, Inc. | Polymorphic kinase anchor proteins and nucleic acids encoding the same |
WO2005060996A2 (en) * | 2003-12-23 | 2005-07-07 | Lauras As | Method of altering the pka type i signalling pathway |
GB0413726D0 (en) | 2004-06-18 | 2004-07-21 | Lauras As | Compounds |
GB0421355D0 (en) * | 2004-09-24 | 2004-10-27 | Univ Oslo | Inhibitors |
GB0518027D0 (en) * | 2005-09-05 | 2005-10-12 | Birkeland Innovasjon As | Compounds |
EP3003290B1 (en) | 2013-06-05 | 2021-03-10 | AgeX Therapeutics, Inc. | Compositions for use in the treatment of wounds in mammalian species |
US11078462B2 (en) | 2014-02-18 | 2021-08-03 | ReCyte Therapeutics, Inc. | Perivascular stromal cells from primate pluripotent stem cells |
US10240127B2 (en) * | 2014-07-03 | 2019-03-26 | ReCyte Therapeutics, Inc. | Exosomes from clonal progenitor cells |
US20230285556A1 (en) * | 2021-09-13 | 2023-09-14 | Omeros Corporation | Methods and compositions for treating cancer |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993019766A1 (en) * | 1992-03-27 | 1993-10-14 | The Regents Of The University Of California | Methods and compositions for restoring impaired cellular immune function |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4568676A (en) * | 1983-11-25 | 1986-02-04 | Thomas Jefferson University | Method of inhibiting aggregation using thromboxane synthetase inhibitor in combination with a cyclic AMP phosphodiesterase inhibitor |
US5276017A (en) * | 1990-09-14 | 1994-01-04 | Trustees Of The University Of Pennsylvania | Therapeutic and diagnostic applications of tropho-uteronectin (TUN) manipulation |
WO1993021929A1 (en) * | 1992-05-01 | 1993-11-11 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Phosphorothioate derivatives of cyclic amp analogues |
WO1994016736A1 (en) * | 1993-01-22 | 1994-08-04 | University Research Corporation | Localization of therapeutic agents |
US5807693A (en) * | 1994-11-23 | 1998-09-15 | Icos Corporation | Calcineurin inhibitory compounds and anchoring protein |
US5795735A (en) * | 1995-07-17 | 1998-08-18 | Icos Corporation | Isolated polynucleotides encoding PKA-binding proteins and methods of producing the proteins recombinantly |
US5969117A (en) * | 1995-08-17 | 1999-10-19 | Hybridon, Inc. | Modified protein kinase a-specific oligonucleotide |
-
1997
- 1997-04-29 NO NO971997A patent/NO971997D0/no unknown
-
1998
- 1998-04-29 CA CA002288215A patent/CA2288215C/en not_active Expired - Fee Related
- 1998-04-29 PT PT98917808T patent/PT1024809E/pt unknown
- 1998-04-29 ES ES98917808T patent/ES2171018T3/es not_active Expired - Lifetime
- 1998-04-29 DE DE69804125T patent/DE69804125T2/de not_active Expired - Fee Related
- 1998-04-29 EP EP98917808A patent/EP1024809B1/en not_active Expired - Lifetime
- 1998-04-29 JP JP54685698A patent/JP2002501499A/ja active Pending
- 1998-04-29 NZ NZ501181A patent/NZ501181A/en unknown
- 1998-04-29 AT AT98917808T patent/ATE213944T1/de not_active IP Right Cessation
- 1998-04-29 DK DK98917808T patent/DK1024809T3/da active
- 1998-04-29 AU AU70865/98A patent/AU738674B2/en not_active Ceased
- 1998-04-29 WO PCT/NO1998/000134 patent/WO1998048809A1/en active IP Right Grant
-
2005
- 2005-05-25 US US11/136,560 patent/US20050250727A1/en not_active Abandoned
-
2009
- 2009-12-25 JP JP2009295046A patent/JP2010111688A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993019766A1 (en) * | 1992-03-27 | 1993-10-14 | The Regents Of The University Of California | Methods and compositions for restoring impaired cellular immune function |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010503652A (ja) * | 2006-09-15 | 2010-02-04 | ローラス エーエス | (Rp)−8−置換cAMPSを製造する方法 |
US8304531B2 (en) | 2006-09-15 | 2012-11-06 | Solvell As | Process for the preparation of an (RP)-8-substituted cAMPS |
Also Published As
Publication number | Publication date |
---|---|
NZ501181A (en) | 2002-03-01 |
AU7086598A (en) | 1998-11-24 |
WO1998048809A1 (en) | 1998-11-05 |
EP1024809A1 (en) | 2000-08-09 |
NO971997D0 (no) | 1997-04-29 |
ES2171018T3 (es) | 2002-08-16 |
DE69804125D1 (de) | 2002-04-11 |
CA2288215C (en) | 2009-08-18 |
CA2288215A1 (en) | 1998-11-05 |
ATE213944T1 (de) | 2002-03-15 |
AU738674B2 (en) | 2001-09-20 |
JP2010111688A (ja) | 2010-05-20 |
PT1024809E (pt) | 2002-07-31 |
US20050250727A1 (en) | 2005-11-10 |
DK1024809T3 (da) | 2002-06-24 |
DE69804125T2 (de) | 2002-10-31 |
EP1024809B1 (en) | 2002-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010111688A (ja) | 免疫調節剤の用途 | |
De Clercq | Novel compounds in preclinical/early clinical development for the treatment of HIV infections | |
Salkowski et al. | Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages | |
Nomura et al. | Inducible nitric oxide synthase in glial cells | |
De Clercq | Antiviral therapy for human immunodeficiency virus infections | |
US7271198B2 (en) | Method of treating autoimmune diseases | |
Kwiatkowski et al. | Beneficial properties of maraviroc on neuropathic pain development and opioid effectiveness in rats | |
Pastan et al. | Molecular manipulations of the multidrug transporter: a new role for transgenic mice 1 | |
WO1997004761A1 (en) | Methods and compositions for treating cell proliferative disorders | |
Perno et al. | Therapeutic strategies towards HIV-1 infection in macrophages | |
WO2020169707A1 (en) | Foxo1 inhibitor for use in the treatment of latent virus infection | |
Fraternale et al. | Macrophage protection by addition of glutathione (GSH)-loaded erythrocytes to AZT and DDI in a murine AIDS model | |
EP2904009B1 (en) | Compounds for treating the remyelination blockade in diseases associated with the expression of herv-w envelope protein | |
Kimura et al. | The absence of interleukin-6 enhanced arsenite-induced renal injury by promoting autophagy of tubular epithelial cells with aberrant extracellular signal-regulated kinase activation | |
US20040132161A1 (en) | Methods and compositions for increasing CD4lymphocyte immune responsiveness | |
Sarkar et al. | The curious case of SARM1: Dr. Jekyll and Mr. Hyde in cell death and immunity? | |
RU2049336C1 (ru) | Способ определения hiv | |
AU6042894A (en) | Soluble T-cell receptor alpha chain and derivatives used as prophylactic and therapeutic agents for autoimmune diseases | |
NO331715B1 (no) | Anvendelse av 4-(4-metylpiperazin-1-ylmetyl)-N-[4-metyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)fenyl]-benzamid eller et farmasoytisk akseptabelt salt derav for fremstilling av et medikament for terapi eller prevensjon av diabetes | |
WO1995006718A2 (en) | Methods of suppressing autoimmune response | |
US7192932B1 (en) | Use of immunomodulating agents | |
JP2000053580A (ja) | 全身性紅斑性狼そうの治療におけるペプチド化合物の使用方法 | |
RU2021810C1 (ru) | Способ воздействия на развитие заболевания, вызванного hiv-вирусом или вирусом, вызывающим сходную биохимическую или клиническую картину | |
Ma | Regulation of IL-12p40 expression by HIV-Nef in human monocytic cells | |
NO325209B1 (no) | Anvendelse av immunmodulerende midler, peptid, hammerhoderibozymer, antisensoligonukleotider, farmasoytiske blandinger og inhibitorer. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050428 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050428 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081202 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090225 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090413 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20090602 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090825 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091225 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100311 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100415 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20100624 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20120305 |